ATE444751T1 - Behandlung von psychosen oder neuropsychiatrischen störungen im zusammenhang mit alzheimer - Google Patents
Behandlung von psychosen oder neuropsychiatrischen störungen im zusammenhang mit alzheimerInfo
- Publication number
- ATE444751T1 ATE444751T1 AT99937263T AT99937263T ATE444751T1 AT E444751 T1 ATE444751 T1 AT E444751T1 AT 99937263 T AT99937263 T AT 99937263T AT 99937263 T AT99937263 T AT 99937263T AT E444751 T1 ATE444751 T1 AT E444751T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- psychoses
- alzheimer
- disorders related
- neuropsychiatric disorders
- Prior art date
Links
- 208000028017 Psychotic disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Chemical Treatment Of Metals (AREA)
- Liquid Crystal Substances (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Liquid Crystal (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9815383.6A GB9815383D0 (en) | 1998-07-15 | 1998-07-15 | Novel method of treatment |
| PCT/US1999/016002 WO2000003717A1 (en) | 1998-07-15 | 1999-07-15 | Method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE444751T1 true ATE444751T1 (de) | 2009-10-15 |
Family
ID=10835581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99937263T ATE444751T1 (de) | 1998-07-15 | 1999-07-15 | Behandlung von psychosen oder neuropsychiatrischen störungen im zusammenhang mit alzheimer |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20020156093A1 (de) |
| EP (1) | EP1104301B1 (de) |
| JP (1) | JP2002520364A (de) |
| KR (1) | KR20010071893A (de) |
| CN (1) | CN1146420C (de) |
| AT (1) | ATE444751T1 (de) |
| AU (1) | AU758936B2 (de) |
| BR (1) | BR9912008A (de) |
| CA (1) | CA2337229A1 (de) |
| CZ (1) | CZ2001150A3 (de) |
| DE (1) | DE69941509D1 (de) |
| GB (1) | GB9815383D0 (de) |
| HU (1) | HUP0103149A3 (de) |
| IL (1) | IL140629A0 (de) |
| NO (1) | NO20010195L (de) |
| NZ (1) | NZ509177A (de) |
| PL (1) | PL345505A1 (de) |
| TR (1) | TR200100088T2 (de) |
| WO (1) | WO2000003717A1 (de) |
| ZA (1) | ZA200100360B (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008921D0 (en) * | 2000-04-11 | 2000-05-31 | Smithkline Beecham Plc | Method of treatment |
| KR100971395B1 (ko) * | 2003-07-23 | 2010-07-21 | 엘지디스플레이 주식회사 | 백 라이트 유닛 |
| JP4792726B2 (ja) * | 2003-10-30 | 2011-10-12 | 日亜化学工業株式会社 | 半導体素子用支持体の製造方法 |
| GB0428170D0 (en) * | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Mono and Combination Therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG48315A1 (en) * | 1989-04-13 | 1998-04-17 | Beecham Group Plc | Novel compounds |
| GB9421472D0 (en) * | 1994-10-25 | 1994-12-07 | Smithkline Beecham Plc | Novel methods |
| GB9615628D0 (en) * | 1996-07-25 | 1996-09-04 | Smithkline Beecham Plc | Formulation |
| AU5716898A (en) * | 1997-01-08 | 1998-08-03 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
| EP1009403A4 (de) | 1997-04-11 | 2002-08-28 | Lilly Co Eli | Verfahren zur behandlung von schizophrenie |
-
1998
- 1998-07-15 GB GBGB9815383.6A patent/GB9815383D0/en not_active Ceased
-
1999
- 1999-07-15 IL IL14062999A patent/IL140629A0/xx unknown
- 1999-07-15 DE DE69941509T patent/DE69941509D1/de not_active Expired - Lifetime
- 1999-07-15 CN CNB998086045A patent/CN1146420C/zh not_active Expired - Fee Related
- 1999-07-15 CA CA002337229A patent/CA2337229A1/en not_active Abandoned
- 1999-07-15 HU HU0103149A patent/HUP0103149A3/hu unknown
- 1999-07-15 AT AT99937263T patent/ATE444751T1/de not_active IP Right Cessation
- 1999-07-15 WO PCT/US1999/016002 patent/WO2000003717A1/en not_active Ceased
- 1999-07-15 NZ NZ509177A patent/NZ509177A/en unknown
- 1999-07-15 PL PL99345505A patent/PL345505A1/xx not_active Application Discontinuation
- 1999-07-15 TR TR2001/00088T patent/TR200100088T2/xx unknown
- 1999-07-15 BR BR9912008-9A patent/BR9912008A/pt not_active IP Right Cessation
- 1999-07-15 JP JP2000559852A patent/JP2002520364A/ja not_active Withdrawn
- 1999-07-15 AU AU52137/99A patent/AU758936B2/en not_active Ceased
- 1999-07-15 CZ CZ2001150A patent/CZ2001150A3/cs unknown
- 1999-07-15 EP EP99937263A patent/EP1104301B1/de not_active Expired - Lifetime
- 1999-07-15 KR KR1020017000561A patent/KR20010071893A/ko not_active Withdrawn
-
2001
- 2001-01-12 ZA ZA200100360A patent/ZA200100360B/en unknown
- 2001-01-12 NO NO20010195A patent/NO20010195L/no not_active Application Discontinuation
-
2002
- 2002-04-17 US US10/124,707 patent/US20020156093A1/en not_active Abandoned
-
2003
- 2003-02-21 US US10/372,577 patent/US6750227B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| GB9815383D0 (en) | 1998-09-16 |
| EP1104301B1 (de) | 2009-10-07 |
| BR9912008A (pt) | 2001-04-10 |
| CA2337229A1 (en) | 2000-01-27 |
| CZ2001150A3 (cs) | 2001-09-12 |
| KR20010071893A (ko) | 2001-07-31 |
| DE69941509D1 (de) | 2009-11-19 |
| AU5213799A (en) | 2000-02-07 |
| HUP0103149A2 (hu) | 2002-01-28 |
| NO20010195D0 (no) | 2001-01-12 |
| AU758936B2 (en) | 2003-04-03 |
| US20020156093A1 (en) | 2002-10-24 |
| IL140629A0 (en) | 2002-02-10 |
| EP1104301A4 (de) | 2004-09-15 |
| ZA200100360B (en) | 2002-03-12 |
| CN1146420C (zh) | 2004-04-21 |
| CN1309564A (zh) | 2001-08-22 |
| PL345505A1 (en) | 2001-12-17 |
| NZ509177A (en) | 2003-05-30 |
| US6750227B2 (en) | 2004-06-15 |
| JP2002520364A (ja) | 2002-07-09 |
| EP1104301A1 (de) | 2001-06-06 |
| TR200100088T2 (tr) | 2001-06-21 |
| WO2000003717A1 (en) | 2000-01-27 |
| HUP0103149A3 (en) | 2003-03-28 |
| US20030125353A1 (en) | 2003-07-03 |
| NO20010195L (no) | 2001-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY130145A (en) | Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders. | |
| NZ332780A (en) | Substituted amines for the treatment of neurological and neuropsychiatric disorders | |
| MY103352A (en) | Piperazinyl-heterocyclic compounds | |
| MY107157A (en) | Quinuclidine derivatives. | |
| GB9406857D0 (en) | Improvements in or relating to organic compounds | |
| IL101960A0 (en) | Substituted 3-aminoquininuclidines | |
| IN172468B (de) | ||
| GR3035957T3 (en) | Use of riluzole for treating aids-related neural disorders | |
| CA2260145A1 (en) | Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 | |
| FI911083A7 (fi) | Menetelmä kolinergisina aineina käyttökelpoisten 1-atsabisyklo/2.2.1/heptaani- tai -/2.2.2/oktaani-3-oni-O-oksiimien valmistamiseksi | |
| DK599789D0 (da) | 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler | |
| BG102589A (en) | 3-azetidinylalkylpiperidines or -pyrrolidines as tachykin antagonists | |
| GR3032122T3 (en) | Novel 2,9-disubstituted-4H-pyrido-[1,2-a]pyrimidin-4-ones. | |
| ATE186908T1 (de) | 1,2,3,4-tetrahydro-9-akridinamine-derivate | |
| ES2096413T3 (es) | Derivado de acido 5-amino-8-metil-7-pirrolidinilquinoleina-3-carboxilico. | |
| SG48415A1 (en) | Process for the purification of a 3-cephem-4-carboxylic acid derivative | |
| DE69941509D1 (de) | Behandlung von Psychosen oder neuropsychiatrischen Störungen im Zusammenhang mit Alzheimer | |
| EA200000242A1 (ru) | Применение фанхинона для лечения болезни альцгеймера | |
| IT1274997B (it) | Procedimento per la produzione di spazzole nonche' macchina per la produzione di spazzole per l'esecuzione del procedimento | |
| HU9201247D0 (en) | Process for the production of condensed diazepinone derivatives and of mnedical preparations containing them as active agents | |
| TR199900141T2 (xx) | Bunama tedavisi ve/veya profilaksisi i�in form�lasyon. | |
| NO940093L (no) | Cholecystokinin-antagonister anvendelige ved behandling av panikk-angrep | |
| CA2222552A1 (en) | N-oxides as antibacterial agents | |
| EP0319073A3 (en) | Cyclo-octane neuroprotective agents | |
| SI0786998T1 (en) | Use of r-(z))-alpha-(methoxyimino)-alpha-(1-azabicyclo 2.2.2) oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |